In this Review, the authors describe the relationships between persistent DNA damage, inflammation and cellular senescence, which represent a common pathway that contributes to the pathology of many conditions, including rheumatic diseases.

Sarcopenia, which involves the generalized loss of skeletal muscle strength and mass, is commonly associated with rheumatoid arthritis. In this Review, the authors discuss the epidemiology, pathophysiology and identification of rheumatoid sarcopenia and present evidence for the therapeutic roles of physical activity, nutrition and pharmacotherapy.

This Evidence-Based Guideline presents the latest treatment recommendations for medication selection in psoriatic arthritis (PsA), covering the six clinical domains of PsA, related conditions and associated comorbidities, and reflecting important advances in the field since the previous update.

Protein phosphatase magnesium-dependent 1A is a negative modulator of transforming growth factor β signalling and a potential new therapeutic target in osteoarthritis.

Results indicate that prophylactic use of co-trimoxazole can reduce infection-related mortality in patients with new-onset anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis.

Expression of the Na⁺-K⁺-ATPase transmembrane ion transporter is upregulated in kidney-infiltrating B cells in lupus-prone mice and is a potential target for reducing renal B cell survival in patients with lupus nephritis.

A newly developed nanobody that simultaneously targets TNF and IL-6 has greater efficacy than individual targeting in rheumatoid arthritis disease-relevant preclinical models.

Neutrophil extracellular trap proteins trigger an accelerated form of osteoclastogenesis that is enhanced by the presence of carbamylated proteins and is linked to bone erosion.

A panel of serum biomarkers identified by proteomic analysis outperforms the best current alternatives for prediction of the progression of osteoarthritis.